Summary of DIA Workshop: Comparability Challenges: Regulatory and Scientific Issues in the Assessment of Biopharmaceuticals

On February 3–4, 2009, a DIA Workshop was held to review and discuss comparability challenges and issues for biotechnology-derived pharmaceuticals. The workshop was held in the Washington, DC, area and was attended by representatives from the FDA and biotech and pharmaceutical industries. The expect...

Full description

Saved in:
Bibliographic Details
Published in:Drug information journal 2010-07, Vol.44 (4), p.485-504
Main Authors: Lewis, Richard M., Cosenza, Mary Ellen
Format: Article
Language:English
Subjects:
Drug Safety and Pharmacovigilance
Pharmacotherapy
Pharmacy
Regulatory Affairs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On February 3–4, 2009, a DIA Workshop was held to review and discuss comparability challenges and issues for biotechnology-derived pharmaceuticals. The workshop was held in the Washington, DC, area and was attended by representatives from the FDA and biotech and pharmaceutical industries. The expectation was to develop a consensus on which data are necessary to provide assurance of comparability for manufacturing changes made to biotechnology products during different stages of development or postmarketing. Numerous case studies were reviewed and discussed to build on best practices and recognize successful approaches to comparability.
ISSN:2168-4790
0092-8615
2168-4804
2164-9200
DOI:10.1177/009286151004400413